State Street Corp Has $49.62 Million Stock Position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

State Street Corp lessened its holdings in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 2.6% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,240,598 shares of the company's stock after selling 32,900 shares during the period. State Street Corp owned 2.18% of Harmony Biosciences worth $49,624,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. nVerses Capital LLC bought a new stake in Harmony Biosciences in the second quarter valued at $36,000. CWM LLC increased its holdings in shares of Harmony Biosciences by 111.7% in the 3rd quarter. CWM LLC now owns 1,469 shares of the company's stock worth $59,000 after acquiring an additional 775 shares during the period. Quarry LP bought a new stake in Harmony Biosciences in the 2nd quarter valued at about $62,000. Quantbot Technologies LP acquired a new position in Harmony Biosciences during the 3rd quarter valued at about $74,000. Finally, Headlands Technologies LLC grew its position in Harmony Biosciences by 1,608.1% in the 2nd quarter. Headlands Technologies LLC now owns 2,545 shares of the company's stock worth $77,000 after purchasing an additional 2,396 shares during the last quarter. Institutional investors and hedge funds own 86.23% of the company's stock.

Insider Transactions at Harmony Biosciences

In other news, insider Jeffrey Dierks sold 21,496 shares of Harmony Biosciences stock in a transaction that occurred on Tuesday, October 29th. The shares were sold at an average price of $40.47, for a total value of $869,943.12. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 30.80% of the company's stock.

Harmony Biosciences Price Performance

NASDAQ HRMY traded up $0.39 on Friday, reaching $34.28. The company's stock had a trading volume of 2,976,575 shares, compared to its average volume of 487,868. Harmony Biosciences Holdings, Inc. has a twelve month low of $28.14 and a twelve month high of $41.61. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.20 and a current ratio of 3.24. The firm's 50 day moving average is $34.25 and its two-hundred day moving average is $34.07. The stock has a market cap of $1.96 billion, a PE ratio of 16.25, a PEG ratio of 0.60 and a beta of 0.79.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last released its earnings results on Tuesday, October 29th. The company reported $0.79 EPS for the quarter, beating the consensus estimate of $0.64 by $0.15. The business had revenue of $186.00 million during the quarter, compared to analyst estimates of $184.07 million. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The business's quarterly revenue was up 16.0% on a year-over-year basis. During the same period in the prior year, the business earned $0.63 earnings per share. As a group, sell-side analysts predict that Harmony Biosciences Holdings, Inc. will post 2.36 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on HRMY shares. Cantor Fitzgerald lifted their price target on Harmony Biosciences from $51.00 to $58.00 and gave the company an "overweight" rating in a report on Wednesday, October 30th. UBS Group initiated coverage on Harmony Biosciences in a research note on Tuesday, September 10th. They set a "buy" rating and a $56.00 target price on the stock. HC Wainwright began coverage on Harmony Biosciences in a research note on Tuesday. They issued a "buy" rating and a $75.00 price target for the company. Mizuho lifted their price objective on shares of Harmony Biosciences from $42.00 to $52.00 and gave the company an "outperform" rating in a research note on Thursday, October 10th. Finally, Raymond James reaffirmed an "outperform" rating and issued a $40.00 price objective on shares of Harmony Biosciences in a report on Thursday, October 10th. Two equities research analysts have rated the stock with a sell rating and eight have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $49.80.

Harmony Biosciences Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.